|
|
|
| Clinical effect of three vasoactive drugs in the treatment of esophageal variceal bleeding caused by cirrhosis |
| XI Yan |
| Office of Rational Drug Use,Lingyuan Central Hospital,Liaoning Province,Linyuan 122500,China |
|
|
|
|
Abstract Objective To investigate the clinical effect and adverse reactions of three vasoactive drugs,Octreotide,Somatostatin and Pituitrin in the treatment of esophageal and gastric variceal bleeding caused by cirrhosis,and to analyze the economy of different drug treatment regimen.Methods From July 2017 to December 2019,according to the three vasoactive drugs (Octreotide,Somatostatin and Pituitrin) 20 patients with esophageal and gastric variceal bleeding caused by cirrhosis treated in Lingyuan Central Hospital,Liaoning Province were selected respectively.The three vasoactive drugs corresponded to three different medication methods and different medication.The clinical effect,adverse reactions and drug economy of different drug use methods were compared and analyzed comprehensively.Results The total effective rates of clinical treatment in Somatostatin group and Octreotide group were higher than those in Pituitrin group,the differences were statistically significant (P＜0.05);during the treatment period,no significant adverse reactions were found in Somatostatin group and Octreotide group,while in Pituitrin group,abdominal pain and increased stool frequency were found in 7 patients,and 1 patient was intolerable due to pain during the treatment period,1 patient was found nausea and vomiting,1 patient was found dizziness,headaches.The drug costs of Somatostatin group and Octreotide group were higher than those of Pituitrin group,the differences were statistically significant (P＜0.05).Conclusion Octreotide and Somatostatin have better clinical effect and lower adverse reactions than Pituitrin in the clinical treatment of patients with esophageal and gastric variceal bleeding caused by cirrhosis，but Pituitrin has price advantage.It is suggested that the clinical treatment plan should be considered comprehensively according to the actual situation of patients.
|
|
|
|
|
|
| [17] |
魏振满，张文瑾，刘丽萍，等.肝硬化上消化道出血3 种药物治疗方案的成本-效果分析[J].中国药房，2002，13（1）：26-28.
|
| [18] |
龚敏，王桂良，林秋满，等.早期生长抑素和/或特利加压素联合内镜处理治疗肝硬化食管胃底静脉曲张破裂出血效果研究[J].中国全科医学，2019，22（36）：4439-4446，4452.
|
| [19] |
丁敏，亢锴.奥曲肽治疗肝硬化合并上消化道出血的疗效和药物经济学评价[J].现代消化及介入诊疗，2016，21（1）：14-16.
|
| [1] |
龚金红，杜沈蓥荧，刘广军，等.血管活性药物治疗肝硬化致食管胃底静脉曲张破裂出血的循证药物经济学评价[J].中国药房，2017，28（2）：152-157.
|
| [2] |
李佳婧，陈道荣.特利加压素与生长抑素治疗食管胃底静脉曲张出血的疗效meta 分析[J].现代医药卫生，2016，32（2）：170-172.
|
| [3] |
和庆章，王桂良，邱萍，等.内镜处理联合国产生长抑素或进口生长抑素治疗食管胃底静脉曲张破裂出血的效果分析[J].中国现代医生，2019，57（26）：40-43，47.
|
| [4] |
王桂良，邱萍，徐林芳，等.内镜下食管静脉曲张套扎术分别联用生长抑素或特利加压素或奥曲肽治疗食管胃底静脉曲张破裂出血住院成本-效果分析[J].中国全科医学，2018，21（15）：1877-1881.
|
| [5] |
石钢，李长清，傅欣，等.两种方案治疗食管胃底静脉曲张破裂出血的成本-效果分析[J].重庆医学，2013，（35）：4316-4317.
|
| [6] |
王琼，王景，邓菁，等.生长抑素和特利加压素单用或联用治疗肝硬化上消化道出血成本-效果分析[J].中国现代医生，2015，53（28）：49-52.
|
| [7] |
占国清，谭华炳，李芳，等.国产与进口生长抑素治疗食管-胃底静脉曲张破裂出血的成本-效果分析[J].临床消化病杂志，2016，28（1）：36-38.
|
| [8] |
王贵良，邱萍，徐林芳，等.生长抑素、特利加压素及奥曲肽治疗食管胃底静脉曲张破裂出血成本-效果分析[J].中国现代医生，2016，54（28）：106-108，116.
|
| [9] |
林秋满，王桂良，邱萍，等.内镜处理联合不同使用时程奥曲肽治疗食管胃底静脉曲张破裂出血的效果-成本分析[J].中国现代医生，2019，57（18）：15-19.
|
| [10] |
翟厚峰，何清，孔晓方.奥曲肽与垂体后叶素联合硝酸甘油、胃复安治疗食管胃底静脉曲张破裂出血[J].中国实用医刊，2011，38（12）：89-90.
|
| [11] |
康洪华，张凤驰.肝硬化食管胃底静脉曲张破裂出血84 例治疗对比分析[J].中国实用医药，2012，7（2）：90-91.
|
| [12] |
刘伟，李珊珊，周磊，等.奥曲肽与垂体后叶素联合治疗肝硬化失代偿期第一次上消化道出血的临床观察[J].中华全科医学，2014，12（10）：1678-1679.
|
| [13] |
冯建东，陆锐明，宁俭.奥曲肽与乖体后叶素治疗急性食管静脉曲张出血64 例临床效果比较[J].中国医药导报，2014，11（13）：67-69.
|
| [14] |
苏晋.不同方案治疗肝硬化上消化道出血的临床治疗方法对比[J].医学信息，2015，28（14）：268-268.
|
| [15] |
张丹，鲍艳霞，张玉军.泮托拉唑联合生长抑素治疗食管胃底静脉曲张性上消化道出血的临床效果评价[J].中国医药指南，2018，16（3）：86-87.
|
| [16] |
夏波.泮托拉唑联合生长抑素治疗食管胃底静脉曲张性上消化道出血的临床效果评价[J].中国医药指南，2018，16（2）：147-148.
|
|
|
|
